Renal denervation with a resistant arterial hypertension: the results of a five-year follow-up

Glybochko, Petr; Svetankova, A. A.; Родионов, А В; Maltseva, A.S.; Sulimov, V. A.; Fоmin, Victоr

doi:10.26442/terarkh201890988-91

Cited by 11 publications

(4 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 17 In contrast, comparable work on the EQ5D in TRH is scarce. Glybochko et al 18 investigated the EQ5D in 14 patients with AF who underwent renal denervation. Carris and Smith 19 reviewed QoL in patients with TRH, but this study did not include the EQ5D.…”

Section: Discussionmentioning

confidence: 99%

Cost-effectiveness of a telemonitoring programme in patients with cardiovascular diseases compared with standard of care

Ziegler,

Öner,

Quadflieg

et al. 2023

Heart

View full text Add to dashboard Cite

ObjectivesThe main aim of this work was to analyse the cost-effectiveness of an integrated care concept (NICC) that combines telemonitoring with the support of a care centre in addition to guideline therapy for patients. Secondary aims were to compare health utility and health-related quality of life (QoL) between NICC and standard of care (SoC).MethodsThe randomised controlled CardioCare MV Trial compared NICC and SoC in patients from Mecklenburg-West Pomerania (Germany) with atrial fibrillation, heart failure or treatment-resistant hypertension. QoL was measured using the EQ-5D-5L at baseline, 6 months and 1 year follow-up. Quality-adjusted life years (QALYs), EQ5D utility scores, Visual Analogue Scale (VAS) Scores and VAS adjusted life years (VAS-AL) were calculated. Cost data were obtained from health insurance companies, and the payer perspective was taken in health economic analyses. Quantile regression was used with adjustments for stratification variables.ResultsThe net benefit of NICC (QALY) was 0.031 (95% CI 0.012 to 0.050; p=0.001) in this trial involving 957 patients. EQ5D Index values, VAS-ALs and VAS were larger for NICC compared with SoC at 1 year follow-up (all p≤0.004). Direct cost per patient and year were €323 (CI €157 to €489) lower in the NICC group. When 2000 patients are served by the care centre, NICC is cost-effective if one is willing to pay €10 652 per QALY per year.ConclusionNICC was associated with higher QoL and health utility. The programme is cost-effective if one is willing to pay approximately €11 000 per QALY per year.

show abstract

Section: Discussionmentioning

confidence: 99%

Cost-effectiveness of a telemonitoring programme in patients with cardiovascular diseases compared with standard of care

Ziegler,

Öner,

Quadflieg

et al. 2023

Heart

View full text Add to dashboard Cite

show abstract

“…Эффективность и безопасность РДН уже в долгосрочной перспективе была показана в отечественном исследовании под руководством Глыбочко П. В., Светанковой А. А. и др. [18] -за 5 лет наблюдения за участниками исследования было показано достоверно значимое снижение САД, ДАД и индекса массы тела при сохранении показателей креатинина плазмы крови в пределах референсных значений. В вышеописанном исследовании также был показан положительный эффект РДН на самооценку качества жизни у участников, кому была выполнена процедура.…”

Section: что известно о предмете исследования?unclassified

Promising areas of renal denervation application

Arablinsky,

Feshchenko,

Shukurov

et al. 2024

Russ J Cardiol

View full text Add to dashboard Cite

The review systematizes the latest data on renal denervation (RDN) potential in the treatment of pathologies associated with sympathetic hyperactivation. Despite the controversial results obtained at the beginning of its clinical application, the antihypertensive effect and safety of RDN were subsequently convincingly proven in a number of large randomized studies, which is reflected in current clinical guidelines. Study of RDN effect on the course of resistant hypertension, positive effects on other conditions associated with sympathetic hyperactivation were also identified. In particular, on the course of chronic kidney disease, chronic heart failure, as well as on the decrease of the frequency of paroxysmal atrial fibrillation and ventricular arrhythmia episodes, which ultimately may help for wider method implementation in routine clinical practice. For a long time, many studies have been aimed at identifying the effect of RDN on carbohydrate metabolism and improving the diabetes control. However, despite this, this issue still remains open and the possible future prospects for using RDN to improve the control and prognosis of diabetes in patients with this pathology are currently unclear.

show abstract

“…In contrast, comparable work on the EQ5D in TRH is scarce. Glybochko and colleagues (18) investigated the EQ5D in 14 patients with AF who underwent renal denervation. Carris and Smith (19) reviewed QoL in patients with TRH, but this study did not include the EQ5D.…”

Section: How the Work Fits With The Literaturementioning

confidence: 99%

Cost-effectiveness of a telemonitoring program in patients with cardiovascular diseases compared to standard of care

Ziegler,

Öner,

Quadflieg

et al. 2023

Preprint

View full text Add to dashboard Cite

ObjectivesThe main aim of this work was to analyze the cost-effectiveness of an integrated care concept (NICC) that combines telemonitoring with the support of a care center in addition to guideline therapy for patients. Secondary aims were to compare health utility and health-related quality of life (QoL) between NICC and standard of care (SoC).MethodsThe randomized controlled CardioCare MV trial compared NICC and SoC in patients from Mecklenburg-West Pomerania (Germany) with atrial fibrillation, heart failure, or treatment-resistant hypertension. QoL was measured using the EQ-5D-5L at baseline, 6 months, and 1 year follow-up. Quality-adjusted life-years (QALY), EQ5D utility scores, visual analogue scale (VAS) scores, and VAS adjusted life-years (VAS-AL) were calculated. Cost data were obtained from health insurance companies, and the payer perspective was taken in health economic analyses. Quantile regression was used with adjustments for stratification variables.ResultsThe net benefit of NICC (QALY) was 0.031 (95%CI: 0.012–0.050; p=0.001) in this trial involving 957 patients. EQ5D index values, VAS-ALs and VAS were larger for NICC compared to SoC at 1 year follow-up (all p≤0.004). Direct cost per patient and year were €323 (CI: €157–489) lower in the NICC group. When 2000 patients are served by the care center, NICC is cost-effective if one is willing to pay 10,652€ per QALY per year.ConclusionNICC was associated with higher QoL and health utility. The program is cost-effective if one is willing to pay approximately 11,000€ per QALY per year.WHAT IS ALREADY KNOWN ON THIS TOPICIntegrated care concepts, i.e., the combination of telemedicine and the reinforcement of patient self-care in a multidisciplinary team together with telephone support, reduce mortality, morbidity, and levels of depression in patients with cardiovascular diseases.WHAT THIS STUDY ADDSThe integrated care concept investigated in the CardioCare MV trial was also associated with higher quality of life, higher health utility, and it is cost-effective if one is willing to pay approximately 11,000 € per quality-adjusted life-year (QALY).HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICYWith the demonstrated cost effectiveness of the integrated care concept, policy makers and health insurance companies are enabled to decide on the introduction of these concepts as standard of care.

show abstract

Renal denervation with a resistant arterial hypertension: the results of a five-year follow-up

Cited by 11 publications

References 2 publications

Cost-effectiveness of a telemonitoring programme in patients with cardiovascular diseases compared with standard of care

Cost-effectiveness of a telemonitoring programme in patients with cardiovascular diseases compared with standard of care

Promising areas of renal denervation application

Cost-effectiveness of a telemonitoring program in patients with cardiovascular diseases compared to standard of care

Contact Info

Product

Resources

About